Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Blank, C.U.
  • (-) = Blank, C.U.
  • (-) ≠ Peeper, D.S.

Refine Results

Resource Type

Availability

Creation Date

Show more

Author

Show more

Language

Search results

  • RSS Feed
(25 - 48 of 84)

Pages

Systemic therapy in advanced nodular melanoma versus superficial spreading melanoma
Association of immune-related adverse event management with survival in patients with advanced melanoma
A cycle of life of T cell activation
Is a history of optimal staging by sentinel lymph node biopsy in the era prior to adjuvant therapy associated with improved outcome once melanoma Patients have progressed to advanced disease?
End-of-life use of systemic therapy in patients with advanced melanoma
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma
BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma
Response to immune checkpoint inhibitors in acral melanoma
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors
Correction to: Neoadjuvant Systemic Therapy (NAST) in patients with melanoma
Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma
Adjuvant treatment for melanoma in clinical practice
The unfavorable effects of COVID-19 on Dutch advanced melanoma care
Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients
Survival of stage IV melanoma in Belgium and the Netherlands
Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors

Pages